- Cash, cash equivalents, and marketable securities of $274.9 million at Q3 2025; runway through at least 2027 - CARLSBAD, Calif., Nov. 5, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (TYRA), a ...
CARLSBAD, Calif., Aug. 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback